Sirolimus has shown promising effects in patients with inactivating mutations in TSC1, TSC2 and STK11 in hamartoma syndromes such as tuberous sclerosis complex and Peutz-Jeghers Syndrome [18-20]. This evidence concerns the gene STK11 and Peutz-Jeghers syndrome.